Patents by Inventor Louise SILVESTRE

Louise SILVESTRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20230037934
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 28, 2022
    Publication date: February 9, 2023
    Inventors: Elisabeth Souhami, Louise Silvestre
  • PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS
    Publication number: 20230028588
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN
    Publication number: 20220347269
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: March 15, 2022
    Publication date: November 3, 2022
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • USE OF AVE0010 FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2
    Publication number: 20220054594
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: July 1, 2021
    Publication date: February 24, 2022
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20220031811
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: May 3, 2021
    Publication date: February 3, 2022
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Patent number: 11026999
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: June 8, 2021
    Inventors: Elisabeth Souhami, Louise Silvestre
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20210128692
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: August 17, 2020
    Publication date: May 6, 2021
    Inventors: Elisabeth Souhami, Louise Silvestre
  • USE OF AVE0010 FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2
    Publication number: 20200353054
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: December 13, 2019
    Publication date: November 12, 2020
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN
    Publication number: 20200338171
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: December 26, 2019
    Publication date: October 29, 2020
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS
    Publication number: 20200330559
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: January 29, 2020
    Publication date: October 22, 2020
    Inventors: Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20200038488
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 3, 2019
    Publication date: February 6, 2020
    Inventors: Elisabeth Souhami, Louise Silvestre
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20190381145
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 19, 2019
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 Patients
    Publication number: 20190134160
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 9, 2019
    Inventors: Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • Insulin Glargine/Lixisenatide Fixed Ratio Formulation
    Publication number: 20190060411
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: August 10, 2018
    Publication date: February 28, 2019
    Inventors: Elisabeth Souhami, Louise Silvestre
  • PREVENTION OF HYPOGLYCEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
    Publication number: 20190054146
    Abstract: A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: February 21, 2019
    Inventors: Louise Silvestre, Gabor Boka, Patrick Miossec
  • Use of AVE0010 for the Treatment of Diabetes Mellitus Type 2
    Publication number: 20190030132
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: April 24, 2018
    Publication date: January 31, 2019
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN
    Publication number: 20180339023
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: April 23, 2018
    Publication date: November 29, 2018
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Use of AVE0010 for the treatment of diabetes mellitus type 2
    Patent number: 9981013
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Publication number: 20180133290
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: July 24, 2017
    Publication date: May 17, 2018
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Patent number: 9950039
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: April 24, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Elisabeth Souhami, Louise Silvestre